Mendelian randomization studies of biomarkers and type 2 diabetes

Endocrine Connections

Volumn 4, Issue 4, 2015, Pages 249-260

  Abbasi, Ali ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Biomarkers; Epidemiology; Genome wide association; Mendelian randomization; Study; Type 2 diabetes

Indexed keywords

ADIPONECTIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA CAROTENE; BILIRUBIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DIMETHYLGLYCINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LINOLEOYL COENZYME A DESATURASE; LIPOPROTEIN A; MACROPHAGE MIGRATION INHIBITION FACTOR; MICRORNA; RESISTIN; SEX HORMONE BINDING GLOBULIN; TRIACYLGLYCEROL; URIC ACID; VITAMIN D; VITAMIN D BINDING PROTEIN;

ARTICLE; DISEASE ASSOCIATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLYCEMIC CONTROL; HUMAN; MENDELIAN RANDOMIZATION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TELOMERE HOMEOSTASIS;

EID: 84959374672     PISSN: None     EISSN: 20493614     Source Type: Journal    
DOI: 10.1530/EC-15-0087     Document Type: Article

References (59)

1. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM & Diabetes Prevention Program Research G. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine 2002 346 393–403. (doi:10.1056/NEJMoa012512)
2. Abbasi A, Stolk RP & Bakker SJ. Identification of relevant biomarkers for type 2 diabetes. Lancet. Diabetes & Endocrinology 2014 2 106–107. (doi:10.1016/S2213-8587(14)70005-1)
3. Lyons TJ & Basu A. Biomarkers in diabetes: hemoglobin A1c, vascular and tissue markers. Translational Research 2012 159 303–312. (doi:10.1016/j.trsl.2012.01.009)
4. Sandhu MS, Debenham SL, Barroso I & Loos RJ. Mendelian randomisation studies of type 2 diabetes: future prospects. Diabetologia 2008 51 211–213. (doi:10.1007/s00125-007-0903-x)
5. Nelson CP, Hamby SE, Saleheen D, Hopewell JC, Zeng L, Assimes TL, Kanoni S, Willenborg C, Burgess S, Amouyel P et al. Genetically Determined Height and Coronary Artery Disease. New England Journal of Medicine 2015 372 1608–1618. (doi:10.1056/NEJMoa1404881)
6. VanderWeele TJ, Tchetgen Tchetgen EJ, Cornelis M & Kraft P. Methodological challenges in mendelian randomization. Epidemiology 2014 25 427–435. (doi:10.1097/EDE.0000000000000081)
7. Nikolopoulos GK, Bagos PG, Tsangaris I, Tsiara CG, Kopterides P, Vaiopoulos A, Kapsimali V, Bonovas S & Tsantes AE. The association between plasminogen activator inhibitor type 1 (PAI-1) levels, PAI-1 4G/5G polymorphism, and myocardial infarction: a Mendelian randomization meta-analysis. Clinical Chemistry and Laboratory Medicine 2014 52 937–950. (doi:10.1515/cclm-2013-1124)
8. Haase CL, Tybjaerg-Hansen A, Qayyum AA, Schou J, Nordestgaard BG & Frikke-Schmidt R. LCAT, HDL cholesterol and ischemic cardiovascular disease: aMendelian randomization study of HDL cholesterol in 54,500 individuals. Journal of Clinical Endocrinology and Metabolism 2012 97 E248–E256. (doi:10.1210/jc.2011-1846)
9. Smith GD & Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. International Journal of Epidemiology 2004 33 30–42. (doi:10.1093/ije/dyh132)
10. Burgess S, Scott RA, Timpson NJ, Davey Smith G, Thompson SG & EPICInterAct Consortium. Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors. European Journal of Epidemiology 2015 30 543–552. (doi:10.1007/ s10654-015-0011-z)
11. Abbasi A, Deetman PE, Corpeleijn E, Gansevoort RT, Gans RO, Hillege HL, van der Harst P, Stolk RP, Navis G, Alizadeh BZ et al. Bilirubin as a potential causal factor in type 2 diabetes risk: a mendelian randomization study. Diabetes 2015 64 1459–1469. (doi:10.2337/db14-0228)
12. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. British Medical Journal 2009 339 b2700. (doi:10.1136/bmj.b2700)
13. Morris AP, Voight BF, Teslovich TM, Ferreira T, Segre AV, Steinthorsdottir V, Strawbridge RJ, Khan H, Grallert H, Mahajan A et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nature Genetics 2012 44 981–990. (doi:10.1038/ng.2383)
14. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, Wheeler E, Glazer NL, Bouatia-Naji N, Gloyn AL et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nature Genetics 2010 42 105–116. (doi:10.1038/ng.520)
15. Besseling J, Kastelein JJ, Defesche JC, Hutten BA & Hovingh GK. Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. Journal of the American Medical Association 2015 313 1029–1036. (doi:10.1001/jama.2015.1206)
16. Brunner EJ, Kivimaki M, Witte DR, Lawlor DA, Davey Smith G, Cooper JA, Miller M, Lowe GD, Rumley A, Casas JP et al. Inflammation, insulin resistance, and diabetes–Mendelian randomization using CRP haplotypes points upstream. PLoS Medicine 2008 5 e155. (doi:10.1371/journal.pmed.0050155)
17. Buijsse B, Boeing H, Hirche F, Weikert C, Schulze MB, Gottschald M, Kuhn T, Katzke VA, Teucher B, Dierkes J et al. Plasma 25-hydroxyvitamin D and its genetic determinants in relation to incident type 2 diabetes: a prospective case-cohort study. European Journal of Epidemiology 2013 28 743–752. (doi:10.1007/s10654-013-9844-5)
18. Chung CM, Lin TH, Chen JW, Leu HB, Yin WH, Ho HY, Sheu SH, Tsai WC, Chen JH, Lin SJ et al. Common quantitative trait locus downstream of RETN gene identified by genome-wide association study is associated with risk of type 2 diabetes mellitus in Han Chinese: a Mendelian randomization effect. Diabetes/Metabolism Research and Reviews 2014 30 232–240. (doi:10.1002/dmrr.2481)
19. Dastani Z, Hivert MF, Timpson N, Perry JR, Yuan X, Scott RA, Henneman P, Heid IM, Kizer JR, Lyytikainen LP et al. Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genetics 2012 8 e1002607. (doi:10.1371/journal.pgen.1002607)
20. De Silva NM, Freathy RM, Palmer TM, Donnelly LA, Luan J, Gaunt T, Langenberg C, Weedon MN, Shields B, Knight BA et al. Mendelian randomization studies do not support a role for raised circulating triglyceride levels influencing type 2 diabetes, glucose levels, or insulin resistance. Diabetes 2011 60 1008–1018. (doi:10.2337/db10-1317)
21. Ding EL, Song Y, Manson JE, Hunter DJ, Lee CC, Rifai N, Buring JE, Gaziano JM & Liu S. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. New England Journal of Medicine 2009 361 1152–1163. (doi:10.1056/NEJMoa0804381)
22. Gan W, Guan Y, Wu Q, An P, Zhu J, Lu L, Jing L, Yu Y, Ruan S, Xie D et al. Association of TMPRSS6 polymorphisms with ferritin, hemoglobin, and type 2 diabetes risk in a Chinese Han population. American Journal of Clinical Nutrition 2012 95 626–632. (doi:10.3945/ajcn.111.025684)
23. Herder C, Klopp N, Baumert J, Muller M, Khuseyinova N, Meisinger C, Martin S, Illig T, Koenig W & Thorand B. Effect of macrophage migration inhibitory factor (MIF) gene variants and MIF serum concentrations on the risk of type 2 diabetes: results from the MONICA/KORA Augsburg Case-Cohort Study, 1984-2002. Diabetologia 2008 51 276–284. (doi:10.1007/s00125-007-0800-3)
24. Huang T, Ren J, Huang J & Li D. Association of homocysteine with type 2 diabetes: a meta-analysis implementing Mendelian randomization approach. BMC Genomics 2013 14 867. (doi:10.1186/1471-2164-14-867)
25. Huang T, Sun J, Chen Y, Xie H, Xu D & Li D. Associations of common variants in methionine metabolism pathway genes with plasma homocysteine and the risk of type 2 diabetes in Han Chinese. Journal of Nutrigenetics and Nutrigenomics 2014 7 63–74. (doi:10.1159/000365007)
26. Interleukin 1 Genetics C. Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis. Lancet. Diabetes & Endocrinology 2015 3 243–253. (doi:10.1016/S2213-8587(15)00034-0)
27. Jensen MK, Bartz TM, Djousse L, Kizer JR, Zieman SJ, Rimm EB, Siscovick DS, Psaty BM, Ix JH & Mukamal KJ. Genetically elevated fetuin-A levels, fasting glucose levels, and risk of type 2 diabetes: the cardiovascular health study. Diabetes Care 2013 36 3121–3127. (doi:10.2337/dc12-2323)
28. Jorde R, Schirmer H, Wilsgaard T, Joakimsen RM, Mathiesen EB, Njolstad I, Lochen ML, Figenschau Y, Berg JP, Svartberg J et al. Polymorphisms related to the serum 25-hydroxyvitamin D level and risk of myocardial infarction, diabetes, cancer and mortality. The Tromso Study. PLoS ONE 2012 7 e37295. (doi:10.1371/journal.pone.0037295)
29. Kamstrup PR & Nordestgaard BG. Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study. Lancet. Diabetes & Endocrinology 2013 1 220–227. (doi:10.1016/S2213-8587(13)70064-0)
30. Kroger J, Zietemann V, Enzenbach C, Weikert C, Jansen EH, Doring F, Joost HG, Boeing H & Schulze MB. Erythrocyte membrane phospholipid fatty acids, desaturase activity, and dietary fatty acids in relation to risk of type 2 diabetes in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. American Journal of Clinical Nutrition 2011 93 127–142. (doi:10.3945/ajcn.110.005447)
31. Leong A, Rehman W, Dastani Z, Greenwood C, Timpson N, Langsetmo L, Berger C, Metastroke, Fu L, Wong BY et al. The causal effect of vitamin D binding protein (DBP) levels on calcemic and cardiometabolic diseases: a Mendelian randomization study. PLoS Medicine 2014 11 e1001751. (doi:10.1371/journal.pmed.1001751)
32. Magnusson M, Wang TJ, Clish C, Engstrom G, Nilsson P, Gerszten RE & Melander O. Dimethylglycine deficiency and the development of diabetes mellitus. Diabetes 2015 64 3010–3016. (doi:10.2337/db14-1863)
33. Perry J R, Ferrucci L, Bandinelli S, Guralnik J, Semba RD, Rice N, Melzer D, Consortium D, Saxena R, Scott LJ et al. Circulating betacarotene levels and type 2 diabetes-cause or effect? Diabetologia 2009 52 2117–2121. (doi:10.1007/s00125-009-1475-8)
34. Perry JR, Weedon MN, Langenberg C, Jackson AU, Lyssenko V, Sparso T, Thorleifsson G, Grallert H, Ferrucci L, Maggio Met al. Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes. Human Molecular Genetics 2010 19 535–544. (doi:10.1093/hmg/ddp522)
35. Peters KE, Beilby J, Cadby G, Warrington NM, Bruce DG, Davis WA, Davis TM, Wiltshire S, Knuiman M, McQuillan BM et al. A comprehensive investigation of variants in genes encoding adiponectin (ADIPOQ) and its receptors (ADIPOR1/R2), and their association with serum adiponectin, type 2 diabetes, insulin resistance and the metabolic syndrome. BMC Medical Genetics 2013 14 15. (doi:10.1186/ 1471-2350-14-15)
36. Pfister R, Barnes D, Luben R, Forouhi NG, Bochud M, Khaw KT, Wareham NJ & Langenberg C. No evidence for a causal link between uric acid and type 2 diabetes: a Mendelian randomisation approach. Diabetologia 2011 54 2561–2569. (doi:10.1007/s00125-011-2235-0)
37. Pfister R, Sharp S, Luben R, Welsh P, Barroso I, Salomaa V, Meirhaeghe A, Khaw KT, Sattar N, Langenberg C et al. Mendelian randomization study of B-type natriuretic peptide and type 2 diabetes: evidence of causal association from population studies. PLoS Medicine 2011 8 e1001112. (doi:10.1371/journal.pmed.1001112)
38. Song Y, Yeung E, Liu A, Vanderweele TJ, Chen L, Lu C, Liu C, Schisterman EF, Ning Y & Zhang C. Pancreatic b-cell function and type 2 diabetes risk: quantify the causal effect using a Mendelian randomization approach based on meta-analyses. Human Molecular Genetics 2012 21 5010–5018. (doi:10.1093/hmg/dds339)
39. Strawbridge RJ, Dupuis J, Prokopenko I, Barker A, Ahlqvist E, Rybin D, Petrie JR, Travers ME, Bouatia-Naji N, Dimas AS et al. Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. Diabetes 2011 60 2624–2634. (doi:10.2337/db11-0415)
40. Trombetta M, Bonetti S, Boselli ML, Miccoli R, Trabetti E, Malerba G, Pignatti PF, Bonora E, Del Prato S & Bonadonna RC. PPARG2 Pro12Ala and ADAMTS9 rs4607103 as "insulin resistance loci" and "insulin secretion loci" in Italian individuals. The GENFIEV study and the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 4. Acta Diabetologica 2013 50 401–408. (doi:10.1007/s00592-012-0443-9)
41. Wang TT, Chen YJ, Sun LL, Zhang SJ, Zhou ZY & Qiao H. Affection of single-nucleotide polymorphisms inmiR-27a,miR-124a, and miR-146a on susceptibility to type 2 diabetes mellitus in Chinese Han people. Chinese Medical Journal 2015 128 533–539. (doi:10.4103/0366-6999.151112)
42. Yaghootkar H, Lamina C, Scott RA, Dastani Z, Hivert MF, Warren LL, Stancakova A, Buxbaum SG, Lyytikainen LP, Henneman P et al. Mendelian randomization studies do not support a causal role for reduced circulating adiponectin levels in insulin resistance and type 2 diabetes. Diabetes 2013 62 3589–3598. (doi:10.2337/db13-0128)
43. Yaghootkar H, Scott RA, White CC, Zhang W, Speliotes E, Munroe PB, Ehret GB, Bis JC, Fox CS, WalkerMet al. Genetic evidence for a normalweight "metabolically obese" phenotype linking insulin resistance, hypertension, coronary artery disease, and type 2 diabetes. Diabetes 2014 63 4369–4377. (doi:10.2337/db14-0318)
44. Ye Z, Haycock PC, Gurdasani D, Pomilla C, Boekholdt SM, Tsimikas S, Khaw KT, Wareham NJ, Sandhu MS & Forouhi NG. The association between circulating lipoprotein(a) and type 2 diabetes: is it causal? Diabetes 2014 63 332–342. (doi:10.2337/db13-1144)
45. Ye Z, Sharp SJ, Burgess S, Scott RA, Imamura F, InterAct C, Langenberg C, Wareham NJ & Forouhi NG. Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study. Lancet. Diabetes & Endocrinology 2015 3 35–42. (doi:10.1016/S2213-8587(14)70184-6)
46. You NC, Chen BH, Song Y, Lu X, Chen Y, Manson JE, Kang M, Howard BV, Margolis KL, Curb JD et al. A prospective study of leukocyte telomere length and risk of type 2 diabetes in postmenopausal women. Diabetes 2012 61 2998–3004. (doi:10.2337/db12-0241)
47. Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, Zeggini E, Huth C, Aulchenko YS, Thorleifsson G et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nature Genetics 2010 42 579–589. (doi:10.1038/ng.609)
48. Van Campenhout A, Van Campenhout C, Lagrou AR, Abrams P, Moorkens G, Van Gaal L & Manuel-y-Keenoy B. Impact of diabetes mellitus on the relationships between iron-, inflammatory- and oxidative stress status. Diabetes/Metabolism Research and Reviews 2006 22 444–454. (doi:10.1002/dmrr.635)
49. Sedlak TW & Snyder SH. Messenger molecules and cell death: therapeutic implications. Journal of the American Medical Association 2006 295 81–89. (doi:10.1001/jama.295.1.81)
50. Miyashita K, Itoh H, Tsujimoto H, Tamura N, Fukunaga Y, Sone M, Yamahara K, Taura D, Inuzuka M, Sonoyama T et al. Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades promote musclemitochondrial biogenesis and prevent obesity. Diabetes 2009 58 2880–2892. (doi:10.2337/db09-0393)
51. Corpeleijn E, Feskens EJ, Jansen EH, Mensink M, Saris WH, de Bruin TW & Blaak EE. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia 2006 49 2392–2401. (doi:10.1007/s00125-006-0383-4)
52. Vessby B, Gustafsson IB, Tengblad S, Boberg M & Andersson A. Desaturation and elongation of Fatty acids and insulin action. Annals ofthe New York Academy of Sciences 2002 967 183–195. (doi:10.1111/j.1749-6632.2002.tb04275.x)
53. Rhee EP, Ho JE, Chen MH, Shen D, Cheng S, Larson MG, Ghorbani A, Shi X, Helenius IT, O’Donnell CJ et al. A genome-wide association study of the human metabolome in a community-based cohort. Cell Metabolism 2013 18 130–143. (doi:10.1016/j.cmet.2013.06.013)
54. Konstantinova SV, Tell GS, Vollset SE, Nygard O, Bleie O & Ueland PM. Divergent associations of plasma choline and betaine with components of metabolic syndrome in middle age and elderly men and women. Journal of Nutrition 2008 138 914–920.
55. Ho JE, Larson MG, Vasan RS, Ghorbani A, Cheng S, Rhee EP, Florez JC, Clish CB, Gerszten RE & Wang TJ. Metabolite profiles during oral glucose challenge. Diabetes 2013 62 2689–2698. (doi:10.2337/db12-0754)
56. Sheikh K, Camejo G, Lanne B, Halvarsson T, Landergren MR & Oakes ND. Beyond lipids, pharmacological PPARalpha activation has important effects on amino acid metabolism as studied in the rat. American Journal of Physiology. Endocrinology and Metabolism 2007 292 E1157–E1165. (doi:10.1152/ajpendo.00254.2006)
57. Ahluwalia TS, Allin KH, Sandholt CH, Sparso TH, Jorgensen ME, Rowe M, Christensen C, Brandslund I, Lauritzen T, Linneberg A et al. Discovery of coding genetic variants influencing diabetes-related serum biomarkers and their impact on risk of type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2015 100 E664–E671. (doi:10.1210/jc.2014-3677)
58. Kraja AT, Chasman DI, North KE, Reiner AP, Yanek LR, Kilpelainen TO, Smith JA, Dehghan A, Dupuis J, Johnson AD et al. Pleiotropic genes for metabolic syndrome and inflammation. Molecular Genetics and Metabolism 2014 112 317–338. (doi:10.1016/j.ymgme.2014.04.007)
59. Vaez A, Jansen R, Prins BP, Hottenga JJ, de Geus EJ, Boomsma DI, Penninx BW, Nolte IM, Snieder H & Alizadeh BZ. In Silico Post Genome-Wide Association Studies Analysis of C-Reactive Protein Loci Suggests an Important Role for Interferons. Circulation. Cardiovascular Genetics 2015 8 487–497. (doi:10.1161/CIRCGENETICS.114.000714)